683 Capital Management LLC Acquires Shares of 56,850 Avalo Therapeutics, Inc. $AVTX

683 Capital Management LLC bought a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 56,850 shares of the company’s stock, valued at approximately $1,032,000. 683 Capital Management LLC owned approximately 0.31% of Avalo Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. UBS Group AG lifted its stake in shares of Avalo Therapeutics by 956.9% in the 4th quarter. UBS Group AG now owns 477,816 shares of the company’s stock worth $8,677,000 after acquiring an additional 432,608 shares during the period. Patient Square Capital LP purchased a new position in shares of Avalo Therapeutics in the 3rd quarter valued at about $1,271,000. Moody Aldrich Partners LLC purchased a new position in shares of Avalo Therapeutics in the 4th quarter valued at about $2,419,000. Cantor Fitzgerald L. P. purchased a new position in Avalo Therapeutics during the 3rd quarter valued at about $1,083,000. Finally, Nan Fung Trinity HK Ltd. purchased a new position in Avalo Therapeutics during the 4th quarter valued at about $3,432,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on AVTX. HC Wainwright dropped their target price on shares of Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Wolfe Research started coverage on shares of Avalo Therapeutics in a research note on Thursday, April 9th. They set an “outperform” rating and a $48.00 price target on the stock. Citizens Jmp decreased their price target on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research note on Thursday, May 14th. Citigroup reissued an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Finally, Piper Sandler reissued an “overweight” rating and issued a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $46.67.

Insider Buying and Selling at Avalo Therapeutics

In other news, insider Paul Varki sold 75,063 shares of Avalo Therapeutics stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the sale, the insider owned 3,634 shares in the company, valued at $73,297.78. This trade represents a 95.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 8,458 shares of Avalo Therapeutics stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $13.09, for a total transaction of $110,715.22. Following the sale, the chief financial officer owned 8,880 shares in the company, valued at $116,239.20. This represents a 48.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 112,586 shares of company stock valued at $2,089,651 over the last ninety days. Corporate insiders own 4.46% of the company’s stock.

Avalo Therapeutics Stock Performance

AVTX opened at $15.40 on Thursday. The stock has a market capitalization of $809.58 million, a PE ratio of -2.82 and a beta of 0.83. Avalo Therapeutics, Inc. has a 1 year low of $4.47 and a 1 year high of $24.27. The company’s 50 day simple moving average is $15.53 and its 200 day simple moving average is $16.12.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. As a group, sell-side analysts expect that Avalo Therapeutics, Inc. will post -2.58 earnings per share for the current fiscal year.

Avalo Therapeutics Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.